Clinical conditions associated with a high antinuclear antibody titer in individuals without autoimmune disease [0.03%]
无自身免疫疾病个体中高抗核抗体滴度相关临床情况
Matthew Chung,John P Shelley,Gul Karakoc et al.
Matthew Chung et al.
Objective: Antinuclear antibodies (ANAs) are present at high titers in 2% of the general population but their clinical significance in individuals without an autoimmune (AI) disease is not known. We tested the hypothesis ...
Risk of Hepatotoxicity in Patients With Gout Treated With Febuxostat or Benzbromarone: comment on article by Sun W et al [0.03%]
痛风患者使用非布司他或苯溴马隆治疗的肝毒性风险：关于孙威等人的来信
Sree Hari Reddy Gadekallu
Sree Hari Reddy Gadekallu
Reply to "Febuxostat use is associated with a significantly greater risk of mild to moderate perturbation of liver function compared to benzbromarone in patients with gout: comment on the article by Sun et al" [0.03%]
关于“Sun等关于氟西布与苯溴马隆相比在痛风患者中对肝功能轻至中度影响的增加风险”的评论的回复
Wenyan Sun,Lingling Cui,Changgui Li
Wenyan Sun
Response for: International Investigation of the Gut-Lung Axis in Systemic Sclerosis-Interstitial Lung Disease [0.03%]
系统性硬化症间质性肺病的肠-肺轴国际调查回应
Kristofer Andréasson,Jennifer S Labus,Arissa Young et al.
Kristofer Andréasson et al.
Gut-lung axis and SSc-ILD: Toward validated multimodal predictive models [0.03%]
肠道-肺轴和SSc-ILD：迈向经验证的多模式预测模型
Gianluca Pagnoni,Aurora Vicenzi,Francesca Coppi
Gianluca Pagnoni
The Effect of Early Tumor Necrosis Factor Inhibitor Initiation on Chronic Opioid Use in Individuals with Axial Spondylarthritis [0.03%]
早期启动肿瘤坏死因子抑制剂对轴向脊柱关节炎患者慢性阿片类药物使用的影响
Eva Petrow,Jose A Meade-Aguilar,Christine Peloquin et al.
Eva Petrow et al.
Objective: Opioid use remains common despite effective therapies for axial spondyloarthritis (axSpA). We assessed whether early tumor necrosis factor inhibitor (TNFi) use is associated with reduced risk of chronic opioid ...
Racial and Ethnic Disparities in the Incidence and Prevalence of Low Back Pain in the United States: A Systematic Review [0.03%]
美国腰痛流行病学种族和民族差异的系统评价
Colleen A Burke,Rebecca Fillipo,Meira Epplein et al.
Colleen A Burke et al.
Objective: This systematic review synthesizes existing evidence to quantify racial and ethnic disparities in LBP incidence and prevalence in the United States, across stages of chronicity (acute, subacute, and chronic LBP...
Serum soluble mediator signatures of lupus nephritis: histological features and response to treatment [0.03%]
系统性红斑狼疮患者肾活检组织病理与血清可溶性介质谱型及其临床意义
Andrea Fava,Catriona A Wagner,Carla J Guthridge et al.
Andrea Fava et al.
Objective: Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to ident...
Diffusion-Weighted Imaging for the Evaluation of the Sacroiliac Joint in Pediatric Patients [0.03%]
儿科患者骶髂关节扩散加权成像评估
Michael L Francavilla,Timothy G Brandon,Dmitry Khrichenko et al.
Michael L Francavilla et al.
Background: Maturational signal in the sacroiliac joint (SIJ) of skeletally immature youth is often misinterpreted as inflammation. Diagnostic tools that improve specificity are greatly needed. Apparent diffusion coeffici...
Re-thinking Strategies for a Pharmaceutical Approach to Pain-related to Connective Tissue Related Raynaud's Phenomenon in the United States [0.03%]
美国与结缔组织相关的雷诺氏现象相关疼痛的药物治疗策略再思考
Tracy M Frech,Charles G Frech,W David Merryman et al.
Tracy M Frech et al.
Introduction: There are no Food and Drug Administration (FDA) approved therapies for Raynaud's phenomenon (RP) treatment in the United States (U.S.). Clinical trials have been challenged by study design. Important advance...